Statistics from Altmetric.com
Neovascular glaucoma (NVG) is a severe consequence of ocular ischaemic disease. The mechanism of intraocular pressure (IOP) elevation is considered to be the increased permeability of the newly formed vessels,1 angle closure by the peripheral anterior synechia and intertrabecular neovascular tissue.2 3 The intravitreal injection of bevacizumab (IVB) was reported to be effective in the regression of new vessels.4 This injection may provide us with sufficient time to treat these patients with retinal photocoagulation. In addition, it may also be used as an adjunctive therapy for a mitomycin C (MMC) trabeculectomy to treat NVG. It remains to be elucidated as to how bevacizumab exerts its effects on the neovascular tissue in NVG. This study was carried out to examine the trabecular meshwork of eyes with NVG following the IVB.
A dose of 1.25 mg (0.05 ml) of IVB (Avastin 100 mg/4 ml, Roche, Reinach, Switzerland) was given in the superotemporal quadrant 4 mm posterior to the limbus of the affected eyes of three patients. The underlying diseases …
Funding: This work was supported in part by Grants in Aid (Nos 16591777 and 18591945) for Scientific Research from the Ministry of Education, Science, Sports and Culture of the Japanese government.
Competing interests: None.
Ethics approval: Ethics approval was provided by the Institutional Review Boards of the University of Occupational and Environmental Health, Japan.
Patient consent: Obtained.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.